Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
Pyxis Oncology to Participate in Upcoming Investor Conferences
Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer
Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026
Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Pyxis Oncology (PYXS) Projected to Post Quarterly Earnings on Tuesday
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Rating of “Moderate Buy” by Brokerages
Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity
Pyxis Oncology, Inc. (NASDAQ:PYXS) Short Interest Update
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Analysts Sound Alarm On Pyxis Oncology's Tiny Trial
Pyxis Oncology, Inc. (PYXS) Discusses Preliminary Phase 1 Data for MICVO in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Transcript
Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Pyxis Oncology to Participate in Upcoming Investor Conferences
Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results
Pyxis Oncology (PYXS) Upgraded to Strong Buy: Here's What You Should Know
5 Small Drug Stocks to Buy as the Industry Shows Some Recovery
Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings
Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Should You Buy Pyxis Oncology, Inc. (PYXS) After Golden Cross?
Pyxis Oncology to Participate in September Investor and Industry Conferences
Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update
Pyxis Oncology to Participate in Two Upcoming Investor Conferences
Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC
5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms
Top Cancer Stocks to Buy to Boost Your Portfolio's Health
Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025
Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference
Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer
Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial
Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201
Pyxis Oncology: Speculative Buy Opportunity With Multiple Catalysts Ahead
Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns
Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data
Pyxis Oncology's Cancer Drug Platform Shows Potential, Analyst Sees Over 190% Upside
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ:PYXS)
Moment Of Truth Approaches For Pyxis Oncology
Pyxis Oncology to Participate in Two Upcoming Investor Conferences
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024
Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger
Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
Q2 2024 EPS Estimates for Pyxis Oncology, Inc. (NASDAQ:PYXS) Decreased by Analyst